Histone Deacetylase Inhibitors
β Scribed by Thomas A. Miller; David J. Witter; Sandro Belvedere
- Publisher
- John Wiley and Sons
- Year
- 2004
- Weight
- 53 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0931-7597
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Histone deacetylase (HDAC), inhibitors represent a new class of targeted antiβcancer agents. Several of these compounds are in clinical trials with significant activity against a spectrum of both hematologic and solid tumors at doses that are well tolerated by the patients. The HDAC inh
## Abstract In cancer cells, an imbalance often exists between histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities, and various drug companies are actively seeking competitive HDAC inhibitors for chemotherapeutic intervention. Cancer cells appear to be more sensitive than nont